Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption.

2005年6月13日 · Alefacept is a recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.

2024年12月20日 · Alefacept injection is used to treat chronic plaque psoriasis, which is a skin disease with red and white scales that don't go away. This medicine is given to patients who have used other medicines that did not work well.

2023年5月3日 · Amevive (alefacept) is a protein that works by affecting the body's immune system to decrease plaques/dead skin cells used for the treatment of moderate to severe chronic plaque psoriasis in people who are candidates for systemic therapy or phototherapy.

2024年8月23日 · Amevive is used to treat plaque psoriasis (raised, silvery flaking of the skin) in adults. Amevive may also be used for purposes not listed in this medication guide. You should not use Amevive if you are allergic to alefacept, or if you have HIV (human immunodeficiency virus).

2021年9月15日 · Alefacept is a recombinant fusion protein of lymphocyte function associated antigen-3 (LFA-3) and immunoglobulin G dimer that acts to block the activation of T cells, and is an immunosuppressive agent that was previously …

Indicated for moderate-to-severe chronic plaque psoriasis. 15 mg IM qWeek x 12 weeks. Regimen of 12 weekly injections recommended. Retreatment with additional 12 week course may be initiated, based...

Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells.

Alefacept (Amevive) is a drug prescribed to treat adult patients with with moderate to severe chronic plaque psoriasis. Side effects, drug interactions, warnings and precautions, dosage, and pregnancy safety information should be reviewed prior to taking this medication.

Alefacept is one of the first biologics in the treatment of psoriasis. It selectively reduces CD45RO(+) memory T cells and inhibits T-cell activation. Clinical data support its safety and efficacy in a substantial subset of patients with psoriasis.